U.S. Diagnostic Stock Boosts Dividends and Invests 1 Trillion Won, Surging Over 2 Trillion in a Day

Quest Diagnostics Inc. (NYSE: DGX) shares climbed 7.33% on the New York Stock Exchange on the 10th, closing at $205.35. Its market capitalization swelled to about $22.8 billion (roughly ₩30 trillion), adding approximately $1.8 billion (around ₩2.4 trillion) in a single day. Trading volume exceeded 1.3 million shares, indicating unusually active turnover.

In its fourth quarter of fiscal 2025, the company reported revenue of $2.8 billion and adjusted earnings per share of $2.42, surpassing analysts’ estimates. It also issued guidance for fiscal 2026, forecasting revenue growth of 6.0% to 7.1% year-over-year. Additionally, Quest Diagnostics raised its quarterly dividend by 7.5% to $0.86 per share and announced an additional $1 billion share repurchase authorization, extending its streak of annual dividend increases to 15 consecutive years.

As the largest independent clinical laboratory company in the United States, Quest Diagnostics provides a wide range of diagnostic services—including blood testing—to hospitals, physician offices, corporations and consumers. One in three American adults and more than half of U.S. hospitals and physicians utilize its testing network, making it a quintessential defensive stock in the diagnostics sector, prized for its stable cash flow and reliable dividends.